Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiaoping Su

Showing results (171-180 of 199) with videos related to

Pageof 20
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2022
An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell CarcinomasXiaofan Lu, Yann Vano, Alexandra Helleux, et al.
Nature Communications|May 26, 2023
SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistanceBujamin H Vokshi, Guillaume Davidson, Nassim Tawanaie Pour Sedehi, et al.
Blood|January 12, 2012
High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterationsMichael W M Kühn, Ina Radtke, Lars Bullinger, et al.
Blood Cancer Journal|March 16, 2025
Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutationsWarren Fiskus, Christopher P Mill, Jessica Piel, et al.
Cancer Research|June 19, 2023
Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell CarcinomaGuillaume Davidson, Alexandra Helleux, Yann A Vano, et al.
Molecular Cancer Therapeutics|March 11, 2014
Concordance of genomic alterations between primary and recurrent breast cancerFunda Meric-Bernstam, Garrett M Frampton, Jaime Ferrer-Lozano, et al.
Hemasphere|January 19, 2026
Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AMLWarren Fiskus, Christopher P Mill, Jessica Piel, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 28, 2009
JAK mutations in high-risk childhood acute lymphoblastic leukemiaCharles G Mullighan, Jinghui Zhang, Richard C Harvey, et al.
Blood|March 4, 2024
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitorWarren Fiskus, Jessica Piel, Mike Collins, et al.
Blood Cancer Journal|May 21, 2021
Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cellsWarren Fiskus, Christopher P Mill, Behnam Nabet, et al.
Pageof 20

Showing results (171-180 of 199) with videos related to

Sort By:
Pageof 20
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2022
An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell CarcinomasXiaofan Lu, Yann Vano, Alexandra Helleux, et al.
Nature Communications|May 26, 2023
SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistanceBujamin H Vokshi, Guillaume Davidson, Nassim Tawanaie Pour Sedehi, et al.
Blood|January 12, 2012
High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterationsMichael W M Kühn, Ina Radtke, Lars Bullinger, et al.
Blood Cancer Journal|March 16, 2025
Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutationsWarren Fiskus, Christopher P Mill, Jessica Piel, et al.
Cancer Research|June 19, 2023
Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell CarcinomaGuillaume Davidson, Alexandra Helleux, Yann A Vano, et al.
Molecular Cancer Therapeutics|March 11, 2014
Concordance of genomic alterations between primary and recurrent breast cancerFunda Meric-Bernstam, Garrett M Frampton, Jaime Ferrer-Lozano, et al.
Hemasphere|January 19, 2026
Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AMLWarren Fiskus, Christopher P Mill, Jessica Piel, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 28, 2009
JAK mutations in high-risk childhood acute lymphoblastic leukemiaCharles G Mullighan, Jinghui Zhang, Richard C Harvey, et al.
Blood|March 4, 2024
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitorWarren Fiskus, Jessica Piel, Mike Collins, et al.
Blood Cancer Journal|May 21, 2021
Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cellsWarren Fiskus, Christopher P Mill, Behnam Nabet, et al.
Pageof 20